Pierre Caloz
Chief Operating Officer bei UNIQURE N.V.
Vermögen: 616 944 $ am 31.03.2024
Profil
Pierre Caloz is currently the Chief Operating Officer at uniQure NV since 2021.
Prior to this, he worked as the SVP, GM-European Union & Asia Pacific Operations at CSL Behring NV.
Caloz completed his undergraduate degree from the University of Geneva in 1996, followed by a graduate degree from the Swiss Federal Institute of Technology in 1997.
He also holds an MBA from Ashridge Business School, which he completed in 2010.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
UNIQURE N.V.
0,25% | 01.03.2024 | 118 643 ( 0,25% ) | 616 944 $ | 31.03.2024 |
Aktive Positionen von Pierre Caloz
| Unternehmen | Position | Beginn |
|---|---|---|
| UNIQURE N.V. | Chief Operating Officer | 17.05.2021 |
Ehemalige bekannte Positionen von Pierre Caloz
| Unternehmen | Position | Ende |
|---|---|---|
CSL Behring NV
 CSL Behring NV BiotechnologyHealth Technology CSL Behring NV engages in the research and development of biotherapies for the treatment of rare and severe illnesses. It offers hematology, immunology, pneumology and specific medicine. The company was founded on February 15, 1995 and is headquartered in Mechelen, Belgium. | Corporate Officer/Principal | - |
Ausbildung von Pierre Caloz
| University of Geneva | Undergraduate Degree |
| Swiss Federal Institute of Technology | Graduate Degree |
| Ashridge Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| UNIQURE N.V. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
CSL Behring NV
CSL Behring NV BiotechnologyHealth Technology CSL Behring NV engages in the research and development of biotherapies for the treatment of rare and severe illnesses. It offers hematology, immunology, pneumology and specific medicine. The company was founded on February 15, 1995 and is headquartered in Mechelen, Belgium. | Health Technology |
